Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety From a RADIANT-4 Subgroup Analysis
Clinical Advances in Hematology and Oncology H&o 14(5 Suppl. 7): 11-13
2016
ISSN/ISBN: 1543-0790
PMID: 27168106
Accession: 057820372
PDF emailed within 1 workday: $29.90
Related References
Yao, J.; Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Pacaud, L.; Ridolfi, A.; Singh, S.; Pavel, M.; Kulke, M. 2016: ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology Journal of Thoracic Oncology 11(11s): S253Yao, J.C.; Oh, D.-Y.; Qian, J.; Park, Y.S.; Herbst, F.; Ridolfi, A.; Izquierdo, M.; Ito, T.; Jia, L.; Komoto, I.; Sriuranpong, V.; Shimada, Y. 2019: Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study Oncotargets and Therapy 12: 1717-1728
Yao, J.C.; Singh, S.; Wolin, E.; Voi, M.; Pacaud, L.B.; Lincy, J.; Sachs, C.; Valle, J.W.; Van Cutsem, E.; Shimada, Y.; Oh, D.-Y. 2015: 134Oradiant-4: Efficacy and safety of everolimus in advanced, nonfunctional neuroendocrine tumors (Net) of the lung or gastrointestinal (Gi) tract Annals of Oncology 26(Suppl 9): ix 40.1-ix 40
Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G. 2015: 5Lba Everolimus in advanced nonfunctional neuroendocrine tumors (Net) of lung or gastrointestinal (Gi) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 Radiant-4 study European Journal of Cancer 51: S709-S710
Fazio, N.; Buzzoni, R.; Delle Fave, G.; Tesselaar, M.E.; Wolin, E.; Van Cutsem, E.; Tomassetti, P.; Strosberg, J.; Voi, M.; Bubuteishvili-Pacaud, L.; Ridolfi, A.; Herbst, F.; Tomasek, J.; Singh, S.; Pavel, M.; Kulke, M.H.; Valle, J.W.; Yao, J.C. 2018: Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis Cancer Science 109(1): 174-181
Lombard-Bohas, C.; Yao, J.C.; Hobday, T.; Van Cutsem, E.; Wolin, E.M.; Panneerselvam, A.; Stergiopoulos, S.; Shah, M.H.; Capdevila, J.; Pommier, R. 2015: Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-3 trial Pancreas 44(2): 181-189
Fazio, N.; Carnaghi, C.; Buzzoni, R.; Valle, J.W.; Herbst, F.; Ridolfi, A.; Strosberg, J.; Kulke, M.H.; Pavel, M.E.; Yao, J.C. 2021: Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: a pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials Cancer 127(15): 2674-2682
Ito, T.; Okusaka, T.; Ikeda, M.; Igarashi, H.; Morizane, C.; Nakachi, K.; Tajima, T.; Kasuga, A.; Fujita, Y.; Furuse, J. 2012: Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial Japanese Journal of Clinical Oncology 42(10): 903-911
Castellano, D.; Bajetta, E.; Panneerselvam, A.; Saletan, S.; Kocha, W.; O'Dorisio, T.; Anthony, L.B.; Hobday, T. 2013: Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase IIi RADIANT-2 study Oncologist 18(1): 46-53
Yao, J.C.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.B.; Rouyrre, N.; Sachs, C.; Valle, J.W.; Fave, G.D.; Van Cutsem, E.; Tesselaar, M.; Shimada, Y.; Oh, D.-Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E. 2016: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 387(10022): 968-977
Kamp, K.; Gumz, B.; Feelders, R.A.; Kwekkeboom, D.J.; Kaltsas, G.; Costa, F.P.; de Herder, W.W. 2013: Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate Endocrine-Related Cancer 20(6): 825-831
Anthony, L.B.; Pavel, M.E.; Hainsworth, J.D.; Kvols, L.K.; Segal, S.; Hörsch, D.; Van Cutsem, E.; Öberg, K.; Yao, J.C. 2015: Impact of Previous Somatostatin Analogue use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase IIi RADIANT-2 Trial Neuroendocrinology 102(1-2): 18-25
Rose, D.B.; Nellesen, D.; Neary, M.P.; Cai, B. 2017: Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic Journal of Medical Economics 20(4): 395-404
Pavel, M.E.; Becerra, C.; Grosch, K.; Cheung, W.; Hasskarl, J.; Yao, J.C. 2017: Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase IIi RADIANT-2 trial Clinical Pharmacology and Therapeutics 101(4): 462-468
Liu, C-Ting.; Chen, M-Huang.; Chen, J-Shi.; Chen, L-Tzong.; Shan, Y-Shen.; Lu, C-Hsien.; Su, Y-Li.; Ku, F-Chen.; Chou, W-Chi.; Chen, Y-Yang. 2016: The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan Asia-Pacific Journal of Clinical Oncology 12(4): 396-402